+ Follow TRASTUZUMAB Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1243290
[Title] => New drug helps people with advanced HER2-positive breast cancer live longer
[Summary] => Roche announced recently that trastuzumab emtansine significantly extended the time people with advanced HER2-positive breast cancer (metastatic and unresectable locally advanced/recurrent) lived without their disease worsening (progression-free survival), compared to people who received a treatment of their physician’s choice in an open-label phase III study called TH3RESA.
[DatePublished] => 2013-10-10 00:00:00
[ColumnID] => 0
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 551569
[Title] => Greater chances of cure for patients with breast cancer
[Summary] => Roche announced recently its new long-term follow up-data from two large pivotal studies evaluating adjuvant trastuzumab in HER2-positive early- stage breast cancer presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).
[DatePublished] => 2010-02-22 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Freeman Cebu Lifestyle
[SectionUrl] => cebu-lifestyle
[URL] =>
)
)
)
TRASTUZUMAB
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1243290
[Title] => New drug helps people with advanced HER2-positive breast cancer live longer
[Summary] => Roche announced recently that trastuzumab emtansine significantly extended the time people with advanced HER2-positive breast cancer (metastatic and unresectable locally advanced/recurrent) lived without their disease worsening (progression-free survival), compared to people who received a treatment of their physician’s choice in an open-label phase III study called TH3RESA.
[DatePublished] => 2013-10-10 00:00:00
[ColumnID] => 0
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 551569
[Title] => Greater chances of cure for patients with breast cancer
[Summary] => Roche announced recently its new long-term follow up-data from two large pivotal studies evaluating adjuvant trastuzumab in HER2-positive early- stage breast cancer presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).
[DatePublished] => 2010-02-22 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Freeman Cebu Lifestyle
[SectionUrl] => cebu-lifestyle
[URL] =>
)
)
)
abtest
October 10, 2013 - 12:00am
February 22, 2010 - 12:00am
